Format

Send to

Choose Destination
J Clin Oncol. 2010 May 10;28(14):2452-9. doi: 10.1200/JCO.2009.27.1627. Epub 2010 Apr 5.

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Author information

1
Department of Surgery, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD 21287, USA. balchch@jhmi.edu

Abstract

PURPOSE:

To determine the survival rates and independent predictors of survival using a contemporary international cohort of patients with stage III melanoma.

PATIENTS AND METHODS:

Complete clinicopathologic and follow-up data were available for 2,313 patients with stage III disease in an updated and expanded American Joint Committee on Cancer (AJCC) melanoma staging database. Kaplan-Meier and Cox multivariate survival analyses were performed.

RESULTS:

Among all 2,313 patients with stage III disease, 81% had micrometastases, and 19% had clinically detectable macrometastases. The 5-year overall survival was 63%; it was 67% for patients with nodal micrometastases, and it was 43% for those with nodal macrometastases (P < .001). Tremendous heterogeneity in survival was observed, particularly in the microscopically detected nodal metastasis subset (from 23% to 87% for 5-year survival). Multivariate analysis demonstrated that in patients with nodal micrometastases, number of tumor-containing lymph nodes, primary tumor thickness, patient age, ulceration, and anatomic site of the primary independently predicted survival (all P < .01). When added to the model, primary tumor mitotic rate was the second-most powerful predictor of survival after the number of tumor-containing nodes. In contrast, for patients with nodal macrometastases, the number of tumor-containing nodes, primary ulceration, and patient age independently predicted survival (P < .01).

CONCLUSION:

In this multi-institutional analysis, we demonstrated remarkable heterogeneity of prognosis among patients with stage III melanoma, especially among those with nodal micrometastases. These results should be incorporated into the design and interpretation of future clinical trials involving patients with stage III melanoma.

PMID:
20368546
PMCID:
PMC2982783
DOI:
10.1200/JCO.2009.27.1627
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center